Exco InTouch Launches New Mobile Tech
Gather™ is an integrated technology system that can be accessed through any internet-connected device and uses a module-based product suite.
Exco InTouch, a provider of patient engagement and data capture solutions for clinical research and healthcare providers, announces Gather™, its integrated technology system that can be accessed through any internet-connected device and replaces independent technology systems used in clinical trials with a module-based product suite.
Primary modules--or products within the suite--include Study Design, Workflow Integration and Study Management for sites and sponsors. For patients, modules are Enrollment, Patient Engagement and eCOA.
Gather™ provides two-way transfer of information between stakeholders and provides a role-based permissions user interface, providing appropriate levels of access, reporting and analytics according to the registered user. For example, Gather™ provides site investigators, healthcare professionals and study managers access to a tailored view of relevant data and results. The interface also ensures identifiable information (PII) is protected.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
